---
title: "600161.SH (600161.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600161.SH/news.md"
symbol: "600161.SH"
name: "600161.SH"
parent: "https://longbridge.com/en/quote/600161.SH.md"
datetime: "2026-05-21T10:07:39.359Z"
locales:
  - [en](https://longbridge.com/en/quote/600161.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600161.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600161.SH/news.md)
---

# 600161.SH (600161.SH) — Related News

### [Blood Products Industry Annual Report Overview: From "Lying Down to Make Money" to Collective Performance Pressure](https://longbridge.com/en/news/284819299.md)
*2026-04-30T18:18:16.000Z*
> The blood products industry is facing collective performance pressure in 2025. Financial reports from seven listed compa

### [BTBP: In the first quarter of 2026, the net profit was 126 million yuan, a year-on-year decrease of 48.45%](https://longbridge.com/en/news/284533257.md)
*2026-04-29T09:23:51.000Z*
> BTBP announced that its revenue for the first quarter of 2026 was 1.142 billion yuan, a year-on-year decrease of 13.36%;

### [BTBP released its 2025 annual performance, with a net profit attributable to the parent company of 1.091 billion yuan, a year-on-year decrease of 29.59%](https://longbridge.com/en/news/280804418.md)
*2026-03-27T13:54:27.000Z*
> BTBP released its 2025 annual report, with revenue of 6.168 billion yuan, a year-on-year increase of 2.26%; net profit a

### [CITIC Construction Investment | 2025 Overview of the Blood Products Industry: The proportion of domestic albumin batch approvals increases, and the development of new products continues to advance](https://longbridge.com/en/news/276006811.md)
*2026-02-15T13:13:05.000Z*
> The research report from CITIC Construction Investment Securities indicates that the domestic blood products industry wi

### [Is the 30 billion leading company changing its leadership, and is the consortium feast over?](https://longbridge.com/en/news/273688450.md)
*2026-01-26T10:06:09.000Z*
> BTBP experienced a change in leadership in January, with Chairman Yang Huichuan resigning and being succeeded by Liang H

### [BTBP faces pressure to change leadership, blood products enter an accelerated phase](https://longbridge.com/en/news/272972241.md)
*2026-01-19T12:19:15.000Z*
> BTBP recently completed a core personnel adjustment, with former chairman Yang Huichuan resigning and Liang Hongjun bein

### [BTBP: Chairman Yang Huichuan resigns](https://longbridge.com/en/news/272838761.md)
*2026-01-16T12:59:14.000Z*
> TianTan Biology announced that due to work adjustments, the company's former chairman Mr. Yang Huichuan has submitted hi

### [BTBP: Director Zhang Jieming has resigned](https://longbridge.com/en/news/271189306.md)
*2025-12-31T08:28:15.000Z*
> BTBP announced that on December 31, 2025, the company's director Zhang Jieming will resign due to work adjustments, with

### [](https://longbridge.com/en/news/270675881.md)
*2025-12-24T01:53:46.000Z*
> The A-share biopharmaceutical sector fluctuated and rose, with PLBIO up over 8%. Other stocks such as BTBP, BOYA BIOLOGY